What question did this study set out to answer?

Evaluate the efficacy and safety of ambrisentan as adjunctive therapy in IgA nephropathy patients.

Ambrisentan as adjunctive therapy for IgA nephropathy: a retrospective single-center analysis

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows ambrisentan effectively reduces proteinuria and hematuria in high-risk IgAN patients, suggesting its potential benefits.

Evaluate the efficacy and safety of ambrisentan as adjunctive therapy in IgA nephropathy patients.
Retrospective analysis of 169 patients with IgA nephropathy receiving ambrisentan for at least 6 months.
Comparison with a propensity score-matched control group of 138 patients receiving standard care.
Assessment of urinary protein-to-creatinine ratio, hematuria, and kidney function at baseline, 3 months, and 6 months.
Median urinary protein-to-creatinine ratio decreased by 58.4% at 6 months with 75.7% of patients achieving a ≥30% reduction.
Significant reduction in hematuria (P < .001) with stable kidney function observed.
Ambrisentan group showed a greater median relative reduction in UPCR compared to controls (−59.7% vs. −53.7%; P = .015).
Increased incidence of anemia noted with decreased hemoglobin levels.

Yang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows ambrisentan effectively reduces proteinuria and hematuria in high-risk IgAN patients, suggesting its potential benefits.

Evaluate the efficacy and safety of ambrisentan as adjunctive therapy in IgA nephropathy patients.
Retrospective analysis of 169 patients with IgA nephropathy receiving ambrisentan for at least 6 months.
Comparison with a propensity score-matched control group of 138 patients receiving standard care.
Assessment of urinary protein-to-creatinine ratio, hematuria, and kidney function at baseline, 3 months, and 6 months.
Median urinary protein-to-creatinine ratio decreased by 58.4% at 6 months with 75.7% of patients achieving a ≥30% reduction.
Significant reduction in hematuria (P < .001) with stable kidney function observed.
Ambrisentan group showed a greater median relative reduction in UPCR compared to controls (−59.7% vs. −53.7%; P = .015).
Increased incidence of anemia noted with decreased hemoglobin levels.

Yang et al. (2026) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark